Inert Gas Bedding: Trade Secret or Patent for a Sleep Tech Innovation?

The Decision That Keeps Founders Up at Night

In 2006, Select Comfort — the company now trading as Sleep Number — filed a lawsuit against a former distributor it accused of misappropriating proprietary air-chamber manufacturing specifications. The litigation ran for years. What made the case instructive was not the verdict but the discovery process: Select Comfort's trade-secret program had logged every contractor agreement, every access-control record, every internal memo that touched chamber geometry. When the moment came to defend the asset, they could prove exactly who knew what and when. Their competitors could buy a finished mattress and measure the chamber dimensions, but they could not reconstruct the pressure-cycling tolerances that made the product perform. That gap — between what a competitor can observe and what they cannot reconstruct — is the only gap that matters in sleep hardware IP strategy.

Inert gas bedding raises the same question with higher stakes and a less obvious answer. Replace air with argon or a nitrogen-argon blend, add a sensor-feedback loop that adjusts chamber pressure in response to sleeper movement and ambient humidity, and you have a system with two very different asset layers. One layer is gas composition: the specific ratio of gases, their purity grade, their interaction with membrane materials. The other is the dynamic architecture: chamber geometry, pressure-cycling timing, the sensor-trigger thresholds that determine when and how the microenvironment resets. Founders in this space almost universally focus their IP instincts on the first layer. That instinct is wrong, and understanding why is the difference between a defensible moat and an exposed position.

What Inert Gas Bedding Actually Does — and Why the Mechanics Matter for IP

Inert gas bedding systems embed sealed or semi-sealed chambers within mattress cores or topper layers. Those chambers are filled with a non-reactive gas — typically argon, nitrogen, or a blend — rather than ambient air. The technical rationale is precise: ambient air carries moisture, oxygen that supports dust-mite metabolism, and particulate allergens. A chamber filled with argon at slight positive pressure creates a microenvironment that physically prevents allergen infiltration without relying on chemical treatments or mechanical filtration. Temperature regulation follows from the gas's thermal conductivity profile; argon conducts heat approximately 67% less efficiently than air, which means a properly engineered chamber can act as a passive thermal buffer without phase-change materials or active cooling.

The more sophisticated implementations add a sensor layer. Pressure transducers detect sleeper position shifts, which alter load distribution across chambers. A microcontroller cycles gas between a reservoir and the active chambers to maintain target pressure and, by extension, target thermal and allergen-barrier performance. This is where the architecture becomes genuinely proprietary: the specific sequence of sensor readings, threshold comparisons, and pressure-release timings is not visible in the finished product. A competitor can purchase a unit, cut it open, and characterize the gas composition to four decimal places using gas chromatography. They cannot recover the firmware logic that governs the cycling sequence from the physical artifact alone.

The Composition-Architecture Reversal

This asymmetry defines what this article calls the Composition-Architecture Reversal: in inert gas bedding systems, the gas mixture is the instinctive patent target but is reconstructible via gas chromatography on any purchased unit; the chamber geometry, pressure-cycling sequence, and sensor-feedback logic constitute the genuinely irreproducible trade-secret layer — inverting the protection priority that most founders assume.

The reversal has two practical consequences. First, patenting the gas composition publicly confirms for competitors exactly which gas ratios to analyze when they buy your product. The patent application that was meant to protect the formula instead serves as a guide for the chromatographic reconstruction. Second, the architecture layer — which is where the real performance differentiation lives — gets left legally naked because founders have already spent their IP budget on patent prosecution for the composition. The competitive moat they spent 18 months building turns out to be a labeled target.

The correct response is not to abandon patents entirely. It is to sequence the protection strategy correctly: trade-secret discipline for the architecture first, narrowly scoped patent claims for the physical-mechanical elements that genuinely cannot be protected any other way, and composition claims only where the specific mixture represents a non-obvious departure from prior art that a competitor could not independently reach.

What Can — and Cannot — Be Patented in This Space

Patent eligibility for inert gas bedding follows the standard post-Alice framework, but the analysis surfaces a specific practical constraint. A claim covering "a bedding system that uses inert gases to improve sleep quality" is facially abstract and will not survive prosecution. A claim covering a specific chamber architecture — defined membrane permeability range, specific geometrical relationship between primary and reservoir chambers, the mechanical valve mechanism that governs pressure transfer — describes a concrete structural configuration with patent weight.

The prior art landscape complicates this. Nitrogen-filled packaging systems (food preservation, industrial insulation) establish substantial prior art on inert gas containment. Sleep Number's own air-chamber portfolio covers pressure-adjustable mattress systems broadly. A new entrant must claim at a level of specificity that carves genuine white space: the particular combination of gas species, membrane material, and pressure-cycling logic that produces a novel result, not the general concept of using inert gases in bedding. That is a narrow target, and narrowly scoped claims are also narrowly enforced. A patent that covers only your exact implementation protects against direct copying but does not prevent a well-resourced competitor from designing a one-step-removed alternative.

This is precisely why the architecture layer belongs in a trade-secret program rather than a patent application. A trade secret has no expiration date, requires no disclosure, and protects against misappropriation even when a competitor arrives at the same result through independent development — provided you can prove your program was rigorous enough to constitute reasonable precaution. That proof is built before the litigation, not during it.

Building a Trade-Secret Program That Holds Under Pressure

The Select Comfort litigation succeeded in part because the company's internal records were contemporaneous and specific. Trade-secret programs fail — courts have dismissed claims outright — when companies cannot demonstrate that they treated the information as secret at the time it was created, not at the time the lawsuit was filed.

For an inert gas bedding company, the program needs to identify the protected assets with precision. "Our manufacturing process" is not adequate specification. "The pressure-cycling firmware, including the sensor-threshold parameters, chamber-sequencing logic, and reservoir-refill timing windows documented in Engineering Specification Rev. 4.2" is. Every asset should be named, versioned, and logged.

Access control must match the sensitivity classification. The gas composition might reasonably be shared with contract manufacturers under NDA. The firmware specification should be shared with no one outside the core engineering team without a documented, time-limited authorization. The failure mode when founders skip this distinction is not a lawsuit — it is a lawsuit they lose, because the court finds that unrestricted sharing of the "secret" destroyed its legal status before the misappropriation occurred.

Employee and contractor agreements require specific attention at two moments: hiring and departure. At hiring, the agreement should define what the employee is permitted to bring from a prior employer (nothing) and what they will create for the company (assigned entirely). At departure, an exit interview should include a documented reminder of ongoing obligations. When a key engineer left a Boston-area sleep tech startup in 2022 and joined a European competitor — a case that did not reach public litigation because the NDA deterred the crossing of specific lines — the startup's leverage derived entirely from the specificity of its departure protocol. The engineer knew exactly which information remained protected, and the new employer's counsel advised accordingly. Vague agreements produce vague deterrence.

The Decision Table: Which Layer Gets Which Protection

The Investor Dimension

Series A diligence for hardware companies increasingly includes an IP audit that goes beyond patent count. Sophisticated investors — particularly those who have watched portfolio companies lose trade-secret cases for want of documentation — now ask for evidence of a trade-secret program, not just a list of pending applications. A company with two narrow patents and a rigorously documented trade-secret program is a more defensible investment than a company with eight broad patent applications and no access-control records. The patents may or may not survive IPR; the trade-secret program, if built correctly, survives as long as the information remains economically valuable and the company maintains its protective measures.

The practical implication: build the trade-secret program in the first 90 days, before any contractor touches the firmware. Patent strategy can be refined over the following 12 months as the competitive landscape clarifies. The sequence matters because trade-secret protection requires continuous reasonable precaution from the moment the asset exists. There is no retroactive trade-secret registration. The clock starts the moment the engineering specification is written down.

Frequently Asked Questions

If a competitor buys my product and runs gas chromatography on it, does my trade secret evaporate?

Only for the composition layer — and only if that layer was your primary protected asset. Gas chromatography recovers the gas species and approximate ratios from a purchased unit, but it does not recover the sensor-feedback architecture, the pressure-cycling timing parameters, or the chamber-geometry tolerances that determine performance. This is why the Composition-Architecture Reversal matters: founders who file composition patents are disclosing the very layer that a competitor could reconstruct analytically anyway, while leaving the irreproducible architecture layer unprotected. The trade secret that survives a chromatographic attack is the one that was never in the gas formula to begin with.

Can I run patents and trade secrets on the same product simultaneously — or does one undermine the other?

They can coexist, but the asset partitioning must be deliberate. A patent application requires full public disclosure of what is claimed. If your patent claim describes the chamber architecture in enough detail to be enabled, you have publicly disclosed that architecture, and it can no longer function as a trade secret. The solution is to claim only the layer you have decided to patent — typically the structural configuration that cannot be protected any other way — while keeping the firmware, process parameters, and sensor logic entirely out of the patent record. Investors should understand that a well-structured dual strategy is a sign of IP sophistication, not indecision.

What happens to my trade-secret program when I need to share specifications with a contract manufacturer in Asia?

This is where most hardware startups make the error that ends careers. Sharing a complete bill of materials and firmware specification with a contract manufacturer under a generic NDA is legally insufficient and practically dangerous. The correct approach segments the disclosure: the CM receives the mechanical specifications needed to fabricate the chambers, but not the firmware. The firmware is loaded by your own engineer on-site or via a secure provisioning system that never leaves your control. The CM's NDA should specifically identify the shared assets by document number and version. When a contract ends, the NDA's survival clause must be explicit and time-unlimited for trade secrets — a standard two-year post-termination window is inadequate for an asset intended to remain proprietary indefinitely.

At what valuation stage does the trade-secret program become investor-facing due diligence?

Earlier than most founders expect: often at seed extension or Series A, particularly for hardware companies where the core innovation is a process or architecture rather than a novel material. Investors running a standard IP audit will request access-control logs, NDA coverage lists, and asset-identification documentation. A company that cannot produce contemporaneous records — meaning records created when the asset was built, not assembled retrospectively in response to the diligence request — will face either a haircut on valuation or a structured closing condition requiring the program to be formalized before funds are released. The cost of building the program correctly at founding is orders of magnitude lower than the cost of reconstructing it under investor scrutiny.

If my gas-cycling firmware is my primary trade secret, what prevents a well-funded competitor from independently developing equivalent logic?

Nothing — and that is the honest answer. Trade secret law does not prevent independent development; it prevents misappropriation. A competitor who hires a different team, runs their own sleep trials, and arrives at a similar pressure-cycling architecture through their own R&D has not violated your trade secret even if the result is functionally identical. This is the structural limitation that sometimes argues for a narrow patent on the specific cycling-sequence mechanism, accepting the disclosure cost in exchange for a legal barrier against independent-development claims. The strategic decision turns on how long your development lead time is, how resource-intensive independent replication would be, and how much of the performance advantage lives in the undisclosable manufacturing refinements that follow the specification — which no competitor can replicate without years of production learning.

This article is for informational purposes only and does not constitute legal advice. Consult qualified IP counsel for guidance specific to your situation.